Live audio/video webcasts of these presentations will be accessible through Eikon’s investor relations website at www.investors.eikontx.com, with an archived edition of the session available later ...

Eikon Therapeutics (NASDAQ:EIKN) outlined its development strategy for selective PARP1 inhibitors and its Werner helicase ...

Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced ...

Detailed price information for Eikon Therapeutics Inc (EIKN-Q) from The Globe and Mail including charting and trades.

US-based biotech Eikon Therapeutics has raised $350.7m in funding to advance its portfolio of cancer candidates. The company’s lead asset, EIK1001, is a systemically administered Toll-like receptor 7 ...

Eikon Therapeutics receives a Sell rating due to lock-up expiry risks despite a promising clinical strategy for EIK1001. EIKN's lead asset, EIK1001, shows encouraging early data in NSCLC and melanoma, ...

Detailed price information for Eikon Therapeutics Inc (EIKN-Q) from The Globe and Mail including charting and trades.

HAYWARD, Calif.--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important ...

Eikon Therapeutics, a company headed by the former Merck executive who steered the cancer drug Keytruda to FDA approval, has raised $350.7 million to support a pipeline that includes a lead drug ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon's leadership team includes ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...